Send to:

Choose Destination
See comment in PubMed Commons below
Drug Resist Updat. 2013 Dec;16(6):108-15. doi: 10.1016/j.drup.2014.02.003. Epub 2014 Feb 28.

Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data.

Author information

  • 1Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland. Electronic address:
  • 2TB and M/XDR-TB Programme, World Health Organization Regional Office for Europe, Copenhagen, Denmark.
  • 3Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
  • 4IML (Institute of Microbiology and Laboratory Medicine), synlab MVZ, Gauting, Germany.
  • 5The Public Health Agency of Sweden, Solna, Sweden; MTC, Karolinska Institutet, Stockholm, Sweden.


To review the latest information about levels of anti-tuberculosis (TB) drug resistance in the European Region of the World Health Organization (WHO) and time-trends in multidrug-resistant TB (resistance to isoniazid and rifampicin; MDR-TB) over the past fifteen years. We analysed data on drug resistance among new and previously treated TB cases reported from 1997 to 2012. Data are collected in surveys of representative samples of TB patients or from surveillance systems based on diagnostic drug susceptibility testing. A total of 15.7% (95% confidence limits (CI): 9.5-21.9) of new and 45.3% (95%CI: 39.2-51.5) of previously treated TB cases are estimated to have MDR-TB in the Region. Extensively drug-resistant TB (MDR-TB and resistance to fluoroquinolones and second-line injectables; XDR-TB) had been reported by 38 of the 53 countries of the region (72%). The proportion of MDR-TB cases with XDR-TB is 11.4% (95%CI: 8.6-14.2). Between 1997 and 2012, population rates of MDR-TB declined in Estonia, Latvia and Germany and increased in the United Kingdom, Sweden and Tomsk Oblasts of the Russian Federation. Surveillance of drug resistance has been strengthened in the WHO European Region, which has the highest proportions of MDR-TB and XDR-TB ever reported globally. More complete data are needed particularly from the Russian Federation.

Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.


Drug-resistance; European Region; MDR-TB; Surveillance; Tuberculosis

[PubMed - in process]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk